Anaplastic large-cell lymphoma (ALCL), a distinct entity of non-Hodgkin\'s lymphoma (NHL) originally described by Stein *et al.*[@b1] in 1985, is characterized by large anaplastic cells expressing CD30 (Ki-1 antigen). Although several ALCL cases have been reported to express antigens of T-cell or B-cell lineage, many cases may lack lymphoid antigens (null type), and rare cases may express both markers[@b2].

Clinically, primary ALCL is divided into three subtypes: primary systemic anaplastic lymphoma kinase (ALK)-positive ALCL, primary systemic ALK-negative ALCL, and primary cutaneous ALCL. Many studies have described the clinicopathologic features of ALCL and explored different treatment strategies, especially for systemic ALCL. By far, no standard chemotherapy regimen has been established for systemic ALCL patients. At diagnosis, ALCL frequently present with many adverse factors, including advanced disease, B symptoms, and extranodal involvement. Thus, many groups have employed aggressive treatment strategies such as third-generation regimens, hybrid regimens, or autologous stem cell transplantation (ASCT)[@b3]--[@b6]. Prospective studies indicated that third-generation regimens were not superior to first-line regimens in terms of response rate or long-term survival[@b7]. Studies of transplantation showed that, whenever it is administrated as an up-front therapy or salvage therapy, 60%--90% of patients survived after ASCT[@b8]--[@b16]. Although high-dose chemotherapy with autologous stem cell support can effectively induce long-term remission and survival in ALCL patients, few studies compared this approach with conventional chemotherapy to validate its superiority. Hence, the role of aggressive treatment strategies in treating ALCL should be reconsidered.

This study aimed to explore the role of ASCT in treating ALCL by comparing its efficacy with conventional chemotherapy. Thus, we retrospectively reviewed the clinical data of 64 patients with systemic ALCL who were diagnosed and treated with conventional chemotherapy or ASCT in our hospital. Here we present the results.

Materials and Methods {#s2}
=====================

Patients and diagnosis {#s2a}
----------------------

A total of 64 patients newly diagnosed with ALCL were studied retrospectively. All these patients were treated in the Department of Medical Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (CAMS & PUMC) between October 1992 and December 2006. The study protocol was approved by the institutional review board of CAMS & PUMC. Informed consent was obtained according to the Declaration of Helsinki. All specimens were reviewed separately by two experienced pathologists, and consensus was reached in all cases. The WHO diagnosis criteria for NHL were adopted for diagnosis. Antibodies against CD30, CD3, CD45RO, CD20, and CD79a were used for immunohistochemical analysis to determine diagnosis and cell origin. Furthermore, ALK and epithelial membrane antigen (EMA) staining were also performed. All antibodies were obtained from Dako Corporation (Denmark).

Staging {#s2b}
-------

Staging was performed according to the Ann Arbor staging systems for Hodgkin disease. At the time of diagnosis, each patient underwent a physical examination, full blood count and biochemical profile, serum lactate dehydrogenase (LDH) determination, chest X-ray, bone marrow aspirate smears, ultrasonography, and computed tomography (CT) or magnetic resonance imaging (MRI) scan. B symptoms were defined as unknown fever (\>38°C) for more than 3 days, weight loss of more than 10% within 6 months, and night sweat. Bulky disease was defined as tumor mass larger than 5 cm.

Treatment strategy and response criteria {#s2c}
----------------------------------------

Anthracycline-based chemotherapy (up to 6 cycles) was given to each patient, and locoregional radiotherapy was added for patients with stage I/II disease or bulky disease. CT scan of target sites was performed every two cycles for response evaluation according to the WHO criteria. Patients with adverse factors such as stage III/IV disease, bulky disease, elevated LDH, or negative ALK expression were candidates for peripheral blood stem cell transplantation (PBSCT). Refractory disease (progression during first-line chemotherapy) or sensitive relapse was also an indication for PBSCT.

Statistical analysis {#s2d}
--------------------

SSPS 10.0 software was used for data analysis. The Kaplan-Meier method was used to estimate overall survival (OS), which were determined from the date of diagnosis to the date of death or the last follow-up visit. Event-free survival (EFS) was estimated from the date of diagnosis to the date of documented failure \[date of the beginning of treatment for patients whose disease progressed while on chemotherapy before achieving complete response (CR), date of relapse, or date of death for any reason\] or to the date of the last follow-up visit for those in first CR. The log-rank test was used to compare survival curves. For continuous variables, *t* test or Mann-Whitney *U* test was employed to analyze the difference between two groups. The Chi-square (χ^2^) test was employed to analyze categorical variables. *P* values less than 0.05 were considered significant.

Results {#s3}
=======

Immunohistochemistry results {#s3a}
----------------------------

Of the 64 patients, 58 (90.6%) had tumors of T-cell lineage as indicated by positive staining for CD3 and CD45RO, 4 (7.8%) had tumors of B-cell lineage as indicated by positive staining for CD20 and CD79a, and 2 (1.6%) had tumors of null phenotype because cells did not express any lineage-specific antigens. Altogether, CD30 expression was examined in 60 patients, ALK expression was examined in 35 patients, and EMA expression was examined in 29 patients; the positive rate for each marker was 96.7% (58/60), 60.0% (21/35), and 51.7% (15/29), respectively.

Patient characteristics {#s3b}
-----------------------

Of the 64 patients, 38 (59.4%) were males and 26 (40.6%) were females (male/female ratio, 1.46:1). The median age at diagnosis was 33 years (range, 8--74 years). Twenty-six (40.6%) patients had stage I disease, 18 (28.1%) had stage II, 9 (14.1%) had stage III, and 11 (17.2%) had stage IV. Fifty-three (82.8%) patients showed peripheral lymph node involvement, whereas mediastinal involvement was noted in 24 (37.5%) patients. Extranodal disease was present in 16 (25.0%) patients. The skin and lung were the most frequently involved sites, and extranodal disease at these sites was observed in 3 patients each. Other extranodal involved sites included the liver (2 patients), bone (2 patients), bone marrow (2 patients), stomach (1 patient), muscle (1 patient), testis (1 patient), nasal cavity (1 patient), and soft tissue (1 patient). B symptoms were present in 28 (43.8%) patients, with fever being the most common. Bulky disease was seen in 25 (39.1%) patients, including 6 patients with tumor diameter larger than 10 cm. In total, 49 patients had complete clinical data for international prognostic index (IPI) scoring. Thirty-eight patients (77.6%) were in the low risk group, 10 (20.4%) were in the low/intermediate risk group, and 1 (2.0%) was in the high/intermediate risk group ([Table 1](#cjc-31-11-532-t01){ref-type="table"}).

###### Characteristics of 64 patients with primary systemic anaplastic large-cell lymphoma

  Characteristic             No. of patients   Percentage (%)
  ------------------------- ----------------- ----------------
  Gender                                      
   Male                            38               59.4
   Female                          26               40.6
  Stage                                       
   I                               26               40.6
   II                              18               28.1
   III                              9               14.1
   IV                              11               17.2
  With extranodal disease          16               25.0
  B symptoms^a^                    28               43.8
   Fever                           25               39.1
   Weight loss                      6               9.4
   Night sweat                     10               15.6
  Bulky disease                    25               39.1
  LDH elevation^b^                 14               28.6
  IPI score^c^                                
   Low                             38               77.6
   Low-intermediate                10               20.4
   High-intermediate                1               2.0
  Immunology                                  
   B cell                           4               7.8
   T cell                          58               90.6
   Null                             2               1.6
  ALK expression^d^                21               60.0

LDH, lactate dehydrogenase; IPI, international prognostic index; ALK, anaplastic lymphoma kinase. ^a^ One patient may have one or more B symptoms. ^b^ LDH was evaluable in 49 patients and elevated in 14. ^c^ A total of 49 patients had complete records for IPI scoring. ^d^ ALK expression was assayed in 35 patients.

Treatment and outcome {#s3c}
---------------------

Of the 64 patients, 51 underwent CHOP chemotherapy (cyclophosphamide, doxorubicin/epirubicin, vincristine, and prednisone), 9 underwent proMACE/cytaBOM chemotherapy (prednisone, doxorubicin, cyclophosphamide, and etoposide, followed by cytarabine, bleomycin, vincristine, and methotrexate with leucovorin rescue), and the other 4 (with stage I/II disease) underwent localized radiotherapy followed by CHEP chemotherapy (cyclophosphamide, doxorubicin/epirubicin, etoposide, and prednisone). Among 54 patients who had targets for response evaluation, CR was achieved in 25 (46.3%) patients, PR in 21 (38.9%) patients, stable disease (SD) in 6 (11.1%) patients, and progressive disease (PD) was observed in 2 (3.7%) patients. For the whole series, the median follow-up period was 51 months (range, 1--167 months). The 4-year EFS and OS rates were 66.6% and 89.6%, respectively. For patients treated with conventional chemotherapy only, the 4-year EFS and OS rates were 70.7% and 88.3%, respectively.

Altogether, 16 patients underwent PBSCT, which was conducted at first remission in 11 patients (6 with CR1 and 5 with PR1) and at second remission in 3 patients (all with CR2); the other 2 proceeded to PBSCT for disease progression during first-line chemotherapy. Conditioning regimens included E-TBI (etoposide, total body irradiation) in 2 patients, CE-TBI (cyclophosphamide, etoposide, total body irradiation) in 2 patients, CBV (cyclophosphamide, carmustine, etoposide) in 3 patients, and BEAM (carmustine, etoposide, cytarabine, melphalan) in 9 patients ([Table 2](#cjc-31-11-532-t02){ref-type="table"}). After a median follow-up of 86.5 months (range, 20--133 months), only 2 patients with negative ALK expression and bone marrow involvement relapsed. One patient (No. 3) relapsed 3 months after PBSCT and was successfully rescued by allogeneic transplantation, whereas the other (No. 2) relapsed 12 months after PBSCT and died 8 months later. The 4-year OS rates for patients treated with PBSCT was 93.3%.

###### Characteristics of patients in the peripheral blood stem cell transplantation (PBSCT) group

  No.    Age/gender   Cell origin     ALK      Stage   Visceral involvement     LDH      Bulk (cm)   Status before PBSCT   Conditioning regimen   Follow-up (months)   Outcome
  ----- ------------ ------------- ---------- ------- ---------------------- ---------- ----------- --------------------- ---------------------- -------------------- ---------
  1         34/M           T           NA        2             None            Normal        5               CR1                  E-TBI                  106            Alive
  2         22/M           T        Negative     4             Skin            Normal        0               CR1                  E-TBI                   24            Died
  3         37/M           B        Negative     4             None            Normal        0               CR1                  CE-TBI                  70            Alive
  4         18/M           T           NA        3            Spleen           Normal        0               PR1                  CE-TBI                 133            Alive
  5         45/M           T        Positive     1        Spleen, liver        Normal        6               PR1                   BEAM                  120            Alive
  6         41/M           T           NA        2             None            Normal        6               RD                    BEAM                  117            Alive
  7         11/M           T           NA        4            Spleen             NA          5               RD                    CBV                    76            Alive
  8         26/F           T        Negative     1             None            Normal        7               PR1                   BEAM                   60            Alive
  9         27/F           T           NA        3             None            Normal        0               CR1                   CBV                   112            Alive
  10        15/M           T        Positive     4             None              NA          0               CR1                   CBV                   109            Alive
  11        22/M           T        Positive     2             None           Elevated       0               CR2                   BEAM                  103            Alive
  12        32/M           T           NA        3             None              NA          0               CR2                   BEAM                   52            Alive
  13        23/F           T        Positive     4             Lung              NA          5               PR1                   BEAM                   97            Alive
  14        46/F           B        Negative     4             Skin              NA          0               CR2                   BEAM                   20            Alive
  15        21/F           T        Positive     4             Lung           Elevated      11               PR1                   BEAM                   56            Alive
  16        12/M         Null       Positive     3             None           Elevated       0               CR1                   BEAM                   48            Alive

M, male; F, female; NA, not available; RD, refractory disease; E-TBI, etoposide and total body irradiation; BEAM, carmustine, etoposide, cytarabine, and melphalan; CBV, cyclophosphamide, carmustine, and etoposide. Other abbreviations as in [Table 1](#cjc-31-11-532-t01){ref-type="table"}.

Because EFS for patients undergoing PBSCT could be compromised by mixed population, we focused the analysis on patients underwent PBSCT at CR1/PR1. Due to inclusion criteria, more patients accompanied with adverse factors when compared with those treated with conventional chemotherapy ([Table 3](#cjc-31-11-532-t03){ref-type="table"}). The EFS and OS rates were 81.8% and 90.9%, respectively. Compared with conventional chemotherapy, PBSCT did not show significant advantages either in EFS (*P* = 0.240) or in OS (*P* = 0.580) when it was applied at first remission (CR1/PR1) ([Figure 1](#cjc-31-11-532-g001){ref-type="fig"}).

###### Comparison of patient characteristics between the conventional chemotherapy group and the transplantation group

  Characteristic               Conventional chemotherapy group (*n* = 39)   Transplantation group (*n* = 11)     *P*
  --------------------------- -------------------------------------------- ---------------------------------- ---------
  Median age (years, range)                    34 (8--68)                             23 (12--45)               0.002
  Sex                                                                                                           0.77
   Male                                        24 (61.5)                                7 (63.6)              
  Stage                                                                                                        \<0.001
   I                                           18 (46.2)                                2 (18.2)              
   II                                          12 (30.8)                                1 (9.1)               
   III                                          5 (12.8)                                3 (27.3)              
   IV                                           4 (10.2)                                5 (45.4)              
  With extranodal disease                       7 (17.9)                                5 (45.5)               \<0.001
  B symptoms                                   17 (43.6)                                6 (54.5)                0.16
  Bulky disease                                17 (43.6)                                5 (45.5)                0.89
  LDH elevation                                 9 (30.0)                                2 (22.2)                0.26
  IPI score                                                                                                    \<0.001
   Low                                         24 (80.0)                                5 (55.6)              
   Low-intermediate                             5 (16.7)                                4 (44.4)              
   High-intermediate                            1 (3.3)                                    0                  
  Immunology                                                                                                    0.031
   B cell                                       1 (2.6)                                 1 (9.1)               
   T cell                                      37 (94.8)                                9 (81.8)              
   Null                                         1 (2.6)                                 1 (9.1)               
  ALK expression                               10 (52.6)                                5 (62.5)                 0.2

Except median age, the values are presented as numbers of patients with percentages in parenthesis.

Abbreviations as in [Table 1](#cjc-31-11-532-t01){ref-type="table"}.

![Event-free survival (EFS) comparison according to the treatment modality.\
The difference of EFS was not significant between patients treated with conventional chemotherapy and those treated with peripheral blood stem cell transplantation (PBSCT) at CR1/PR1.](cjc-31-11-532-g001){#cjc-31-11-532-g001}

Prognostic factors {#s3d}
------------------

In patients undergoing conventional chemotherapy, univariate analysis showed that B symptoms (*P* = 0.001) and stage III//IV (*P* = 0.008) indicated significantly lower EFS, whereas bulky disease (*P* = 0.075), negative ALK expression (*P* = 0.059), and age ≤ 60 years (*P* = 0.054) showed a tendency towards lower EFS. Compared with conventional chemotherapy, PBSCT significantly improved the EFS of patients with B symptoms (100% vs. 50.8%, *P* = 0.027) or with bulky disease (100% vs. 52.8%, *P* = 0.045) when it was applied as an up-front strategy ([Figures 2](#cjc-31-11-532-g002){ref-type="fig"} and [3](#cjc-31-11-532-g003){ref-type="fig"}). However, PBSCT did not provide any additional survival benefit compared with conventional chemotherapy in patients with stage III/IV disease (75% vs. 43.8%, *P* = 0.130), negative ALK expression (33.3% vs. 50.0%, *P* = 0.900) or younger age (81.8% vs. 66.0%, *P* = 0.140). In terms of OS, only 8 patients died in this cohort (1 in the PBSCT group and 7 in the conventional chemotherapy group). Thus, there were not enough censored events for statistical analysis to demonstrate the superiority of PBSCT in any stratified populations.

![EFS comparison according to the treatment modality in patients with B symptoms.\
Patients treated with PBSCT had significantly higher EFS rate than those treated with conventional chemotherapy.](cjc-31-11-532-g002){#cjc-31-11-532-g002}

![EFS comparison according to the treatment modality in patients with bulky disease.\
Patients treated with PBSCT had significantly higher EFS rate than those treated with conventional chemotherapy.](cjc-31-11-532-g003){#cjc-31-11-532-g003}

Discussion {#s4}
==========

ALCL is a rare disease, accounting for less than 5% of NHL[@b2],[@b17],[@b18]. Clinically, it is characterized by the frequent presence of adverse factors such as advanced disease, B symptoms, and extranodal involvement[@b4],[@b19]--[@b22]. In terms of treatment, no standard strategy has been established for systemic ALCL patients. Because many adverse factors are present at diagnosis, more aggressive treatment modalities such as leukemia-like regimens or high-dose chemotherapy with stem cell support have been considered by many groups. Statistically, 60%--90% of ALCL patients, especially those with ALK-positive disease, achieved long-term survival after stem cell transplantation whenever it was administered as an up-front or salvage therapy[@b8]--[@b16]. However, these studies were all single arm, which makes it difficult to draw a definitive conclusion about the superiority of transplantation. In addition, in many studies concerning conventional chemotherapy, the long-term OS rates ranged from 62% to 85% with a median follow-up time longer than 5 years, which was similar to the results of transplantation[@b3]--[@b5]. Therefore, it is necessary to compare conventional chemotherapy and transplantation in one setting to further evaluate the efficacy of transplantation on systemic ALCL. In our study, 64 patients underwent conventional chemotherapy and 16 proceeded to PBSCT thereafter. Because patient statuses at transplantation were not the same, we focused our analysis on 11 patients underwent PBSCT at CR1/PR1 to explore the efficacy of PBSCT as an up-front modality. Compared with conventional chemotherapy treatment in 48 patients, PBSCT did not show significant survival improvement either in EFS (*P* = 0.240) or in OS (*P* = 0.580).

For most study groups, the reason for employing aggressive modalities including PBSCT on ALCL has been adverse factors frequently present at diagnosis. However, factors indicating poor prognosis were mostly identified in other aggressive lymphomas such as diffuse large B-cell lymphoma (DLBCL)[@b23]. In ALCL, some studies failed to show that these aggressive factors had the same prognostic value as they did in other lymphoma subtypes[@b4],[@b5]. Moreover, based on the findings of a study conducted in DLBCL, only patients with specific factors such as elevated LDH level or high IPI score benefit from PBSCT[@b24]. Hence, re-evaluation of these factors in ALCL patients is necessary.

Among patients undergoing conventional chemotherapy in our study, B symptoms (*P* = 0.001) and stage III/IV (*P* = 0.008) indicated significantly lower EFS rate, whereas the significance of bulky disease (*P* = 0.075), negative ALK expression (*P* = 0.059), and age ≤ 60 years (*P* = 0.054) was marginal. Other factors such as elevated LDH level, involvement of more than one extranodal site, and higher performance status, which were unanimously found to indicate poor prognosis in many studies on aggressive lymphoma, were not significant (data not shown). Thus, we confined our analysis to the five adverse factors that had an effect on survival. Our results showed that PBSCT could significantly improve the EFS of patients with B symptoms (100% vs. 50.8%, *P* = 0.027) or bulky disease (100% vs. 52.8%, *P* = 0.045) when it was applied as an up-front strategy. However, PBSCT yielded similar EFS as conventional chemotherapy for patients with stage III/IV disease (*P* = 0.130), negative ALK expression (*P* = 0.900), or younger age (*P* = 0.140).

ALK expression is an important prognostic factor that is used to evaluate the long-term survival of ALCL patients. For primary systemic ALCL patients, those without ALK expression have significantly lower 5-year survival rate than those with ALK expression[@b19],[@b25],[@b26]. However, in our study, negative ALK expression showed only marginal significance towards poor EFS for patients undergoing conventional chemotherapy. It should be noted, however, that some studies suggest that the significance of ALK expression differs in adult and child patients (\<15 years). More specifically, the ALK expression rate in childhood patients was reported to be higher than that in adult patients[@b6],[@b27]--[@b30]. Furthermore, ALK expression in younger patients did not have prognostic value in some studies[@b3],[@b6]. Based on these results, patients younger than 15 in our study were ruled out from further analysis (*n* = 5, with ALK expression analyzed in 2 patients and identified as positive in both). Consequently, the difference of EFS between patients with ALK-negative and ALK-positive disease became significant (45.5% vs. 81.8%, *P* = 0.021). Although this result could not lead to the conclusion that there is indeed a difference in the significance of ALK expression in children and adults, the role of negative ALK expression in indicating poor survival seems more definite in adult ALCL patients.

In our series, PBSCT was conducted in 4 ALK-negative patients (3 at CR1/PR1, 1 at CR2). Two out of 3 patients who underwent PBSCT at CR1/PR1 relapsed. One was successfully rescued by allogeneic transplantation and the other died within 8 months after relapse. Consequently, compared with conventional chemotherapy, PBSCT at CR1/PR1 did not show superiority either in EFS or in OS. Another single-arm study conducted by Zamkoff *et al.*[@b31] explored the efficacy of ASCT in chemosensitive relapsed ALK-negative patients. Of 16 patients recruited, 9 died of disease, 4 relapsed, 1 succumbed to secondary acute myeloid leukemia, and 1 was lost to follow-up. Only 1 patient was alive free of disease at 6 years after transplantation. Therefore, for patients with ALK-negative ALCL, PBSCT showed unsatisfactory results when it was applied as first-line therapy or salvage therapy. Brand new treatment methods are needed to improve the dismal prognosis of these patients.

To our knowledge, our study is the first case-control study to explore the efficacy of PBSCT on ALCL. We show here that when compared with conventional chemotherapy, PBSCT improved the EFS of patients with specific adverse factors. In terms of OS, the improvement was not significant. Prolonged time of follow-up is needed because the long-term survival of ALCL seems longer than that of other subtypes of aggressive lymphoma[@b8],[@b14],[@b23]. Additionally, similar to other studies concerning ALCL, our study was limited by relatively smaller samples and retrospective study design. Prospective study is necessary to further clarify the role of PBSCT in treating ALCL patients.
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